Business Wire

Nocturia: the most common cause of a poor night’s sleep, say experts on World Sleep Day

Jaa

On World Sleep Day, scientists are highlighting the number one reason that people are waking up at night – nocturia (otherwise known as the need to get up and urinate more than once during the night).1,2 It often has one or more contributing factors such as an overproduction of urine, reduced bladder capacity; certain illnesses and medications are also potential contributors.2,6 Although it is most common in older adults, nocturia can affect people of all ages and frequent sleep disturbances significantly impact daily living and can be a sign of more serious health conditions.2,3,4,5

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180315005990/en/

“Nocturia’s disruption to deep sleep results in reduced productivity and alertness that can affect multiple areas of an individual’s life during the day,” said Jens-Peter Nørgaard, Medical Director of Ferring Pharmaceuticals and Professor of Urology at Ghent University, Belgium. “From making it difficult to manage a busy daily schedule to negatively impacting productivity at work, sleep disruption has significant impact far beyond fatigue or night-time inconvenience.”

The effect that sleep disruption can have was measured recently in a study by Nokia Health, which designs smart health devices and apps. In the study sleep patterns were measured using Nokia sleep sensors and compared to self-reported quality of sleep. Of the over 19,000 people surveyed it was shown that frequency of nightly awakenings was the most important factor in getting a good night’s sleep – more than the total duration of sleep or the time people went to bed.7

Lack of sleep from nocturia can lead to impaired daytime functioning, as well as reduced productivity and alertness.3,4,5 These frequent sleep interruptions are important as uninterrupted sleep is needed to sustain physical (including the immune system), mental and emotional health.8

“People often ignore sleep disturbance from nocturia, but this can produce significant disruption to daytime functioning,” said Dr. Andrew Krystal, Professor of Psychiatry and Behavioral Science at University of California, San Francisco. “It is important this is discussed with a healthcare professional, as this disruption is not just harmful in itself but can also be an indicator of more serious health conditions.”

Nocturia can also be a symptom of more serious health problems such as high blood pressure, diabetes and heart disease.2 The impact of sleep disturbances can also lead to greater risk of serious health conditions such as increased risk of diabetes, weakened immune systems and heart disease.9 Similarly, individuals who suffer from chronic sleep disturbances experience reduced cognitive functioning, which can impact productivity, relationships and careers.8

About World Sleep Day
World Sleep Day is an annual event intended to be a celebration of sleep and a call to action on important issues related to sleep. It is organised by the World Sleep Day Committee of the World Sleep Society (founded by World Association of Sleep Medicine and the World Sleep Federation) and will take place on Friday 16th March 2018.10

About Ferring Pharmaceuticals:
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative and personalised healthcare solutions to help mothers and babies, from conception to birth. Founded in 1950, Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Learn more at www.ferring.com and @Ferring, or connect with us on Facebook, Instagram and LinkedIn.

Ferring is a proud supporter of World Sleep Day

1 Benefield LE. Facilitating Aging in Place: Safe, Sound, and Secure, An Issue of Nursing Clinics. 2014

2 National Association for Continence. Nocturia web page. Last accessed 2017.

3 Bliwise DL et al. J Clin Sleep Med 2015;11:53–5.

4 Bliwise DL et al. Eur Urol Suppl 2014;13:e591–e591a.

5 Kobelt G, Borgstrom F, Mattiasson A. Productivity, vitality and utility in a group of healthy professionally active individuals with nocturia. BJU Int. 2003;91(3):190–5

6 Park, H.K and Kim, H.G., Current Evaluation and Treatment of Nocturia, Korean J Urol. Aug 2013; 54(8): 492–498. page 492

7 Roitmann, E., O. Bellahsen, and A. Chieh. "Perceived sleep quality of sleep profiles derived from connected sleep detector data." Sleep Medicine 40 (2017): e281-e282.

8 Laureanno, P. Ellsworth, P., Demystifying Nocturia: Identifying the Cause and Tailoring the Treatment. Urol Nurs. 2010;30(5):276-287.

9 Orzel-Gryglewska, J. Consequences of Sleep Deprivation. International Journal of Occupational Medicine and Environmental Health 2010; 23(1): 95-114. doi:10.2478/v10001-010-0004-9.

10 World Sleep Day website. Homepage. [Last accessed February 2017] Available at: www.worldsleepday.org

Contact information

Ferring Pharmaceuticals
Lindsey Rodger
Senior Manager, Corporate Communications
+41 58 451 40 23 (direct)
+41 79 191 0486 (mobile)
lindsey.rodger@ferring.com
or
Bhavin Vaid
Head of Corporate Communications
+41 58 301 09 52 (direct)
+41 79 191 06 32 (mobile)
bhavin.vaid@ferring.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Proteus Digital Health® Founder to Present at World Economic Forum in Davos21.1.2019 21:54Tiedote

Proteus Digital Health® announced today that Andrew Thompson, its President, Chief Executive Officer and Co-Founder, will present on the progress of Proteus’ digital medicines to improve patient treatment and outcomes at the 2019 World Economic Forum Annual Meeting in Davos-Klosters, Switzerland. Mr. Thompson will present on the official programme: With leaders from financial and academic institutions to address “Theory of the Firm in a World of Digital Ecosystems,” on Tuesday, January 22 beginning at 9:45 a.m. CET in the Congress Centre, Jakobshorn; and Joining state and religious leaders in the Open Forum “Bridging Science with Society,” scheduled to begin at 9:00 a.m. CET on Friday, January 25 at the Swiss Alpine High School Auditorium. This session will be live-streamed on TopLink and the Forum website. Mr. Thompson will also present at two other events during the World Economic Forum Meeting: January 22 at 8:05 p.m., Polish House: Mr. Thompson will provide a keynote address on the

CNIM Is to Equip the French Navy with 14 New Standard Amphibious Landing Craft (EDA-S)21.1.2019 21:36Tiedote

CNIM - in partnership with Socarenam, Mauric and CNN MCO - has been awarded the contract to replace the French Navy's landing crafts. Fourteen new Standard Amphibious Landing Crafts (EDA-S) are to be built over a ten-year period. This contract reasserts CNIM's status as a key partner to the French Navy and a European leader in the area of amphibious operations, supplying the complementary innovative vessels: EDA-S and EDA-R (already in service in the French Navy, designed by CNIM). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190121005420/en/ CNIM is to equip the French Navy with 14 new Standard Amphibious Landing Craft (EDA-S) - (c) CNIM Next-generation of vessels designed by CNIM "Winning this European tender reasserts CNIM's status as experts in amphibious craft design. CNIM is to replace the French Navy's existing landing craft with fourteen new Standard Amphibious Landing Craft, also called EDA-S", notes Philippe Demi

Naspers Progresses Plans to List MultiChoice Group Limited and Unbundle Its Shares in MultiChoice Group to Naspers Shareholders21.1.2019 19:04Tiedote

On 17 September 2018, Naspers Limited (JSE: NPN; LSE: NPSN) announced its intention to list its video entertainment business separately on the Johannesburg Stock Exchange (JSE) as MultiChoice Group Limited (MultiChoice Group) and simultaneously unbundle its shares in this business to Naspers shareholders. It is expected that the Admission and dealings in the Shares will commence on Wednesday, 27 February 2019. In relation to the Admission, MultiChoice Group today published a pre-listing statement compliant with the requirements of the JSE. MultiChoice South Africa (MCSA), MultiChoice Africa, Showmax and Irdeto and their subsidiaries and affiliates, will, among others, be subsidiaries of MultiChoice Group. MultiChoice Group is the leading video entertainment operator on the African continent, with an extensive local and international content offering. It is one of the fastest-growing pay-TV broadcast providers globally and provides entertainment to around 14 million households across 50

MultiChoice Group Limited (MCG) Today Released Its Pre-Listing Statement in Compliance with the JSE Listings Requirements21.1.2019 18:59Tiedote

Naspers Limited (JSE: NPN; LSE: NPSN) : MultiChoice Group Limited (MCG) today released its pre-listing statement in compliance with the JSE Listings Requirements (www.multichoice.com) providing further details about its listing on the Johannesburg Stock Exchange (JSE). Trading in MCG shares is expected to commence on the JSE on Wednesday, 27 February 2019. As announced on 17 September 2018, MCG will include, amongst others, MultiChoice South Africa (MCSA), MultiChoice Africa, Showmax, as well as the global digital platform security provider, Irdeto and all their subsidiaries and affiliates (“the Group”). Calvo Mawela, Group Chief Executive Officer of MCG said: “We believe the listing of MultiChoice provides an excellent opportunity to invest in the leading provider of video entertainment on the African continent. MCG brings an incomparable local and international content offering to around 14-million households and is one of the fastest growing pay-TV broadcast providers globally. With

ResMed’s First Top-of-Head CPAP Mask, AirFit N30i, Now Available across U.S.21.1.2019 17:05Tiedote

ResMed (NYSE: RMD, ASX: RMD), today introduced AirFit N30i, its first top-of-head-connected nasal CPAP mask, across the United States, with a newly designed nasal cradle cushion that sits just under the wearer’s nose. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190121005035/en/ AirFit N30i nasal CPAP mask, front view (Photo: Business Wire) The top-of-head connection keeps tubing out of the wearer’s way, letting them move and sleep in any position. The nasal cradle cushion – ResMed’s first – is designed to reduce facial markings and irritation. AirFit N30i is also convenient for equipment providers and sleep labs – it fits 96 percent of PAP users with just two frame sizes and four cushion sizes. How AirFit N30i compares to the market-leading nasal top-of-head mask In side-by-side comparisons, three out of four users preferred AirFit N30i over the other nasal mask with a top-of-head connection. A majority stated they loved

Metabolon Appoints Michael Rasche as President of International Business21.1.2019 16:06Tiedote

Metabolon, the world leader in metabolomics, today announced that Michael Rasche joined the company as President of International Business. Michael will report to Rohan Hastie, Metabolon’s President and CEO, and become a member of the corporate executive team. He will lead all of Metabolon's international business activities with a strong focus on customer and team expansion. "We are thrilled to have Michael join the Metabolon team," said Hastie. "Michael brings a wealth of commercial and business experience across multiple areas of life sciences, from Pharma to Diagnostics and Biotech. I know he will make an immediate impact on our existing and future customers." "I am very excited to become part of the Metabolon success story," added Rasche. "I will passionately lead our team to drive accelerated business expansion across all international markets. Our Precision Metabolomics™ technology is delivering biomarker discoveries, innovative diagnostic tests, and groundbreaking data in genom

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme